Good prognosis ability of Oral-M® in patients with oral precancerous lesion
|
|
Good prognosis ability of Oral-M® in patients with oral precancerous lesion |
 |
New Taipei City, July 1st, 2021. iStat Biomedical Co., Ltd. (iStat Co.), published Oral-M® 5-year follow-up data in Oral Diseasesa.
This is a follow up hospital-based cohort study conducted in 2012-2017, a continuous investigation of 171 patients with normal mucosa and oral potentially malignant disorders (OPMD) from the recruited subjects of Oral-M® clinical performance study at National Taiwan University Hospital (NTUH)a,b.
Oral-M® (ZNF582 methylation test) by its objective and noninvasive nature, can serve as an effective prognostic tool for disease progression, including progression or malignant transformation of oral lesions in patients with normal oral mucosa and OPMDs.Results demonstrate that patients with higher ZNF582 and PAX1 methylation levels at baseline had a higher incidence of disease progression. In particular, ZNF582 methylation level is the only significant and independent predictor of disease progression after several adjustments of studied factors.
- Juan, Y.-C., Su, Y.-F., Bai, C.-H., Fan, Y.-C., Kuo, T.-T., Ko, H.-H., Peng, H.-H., Chiang, C.-P., Fwu, C.-W., & Cheng, S.-J. (2021). ZNF582 hypermethylation as a prognostic biomarker for malignant transformation of oral lesions. Oral Diseases, 00, 1–10. https://doi.org/10.1111/odi.13946
- Cheng, S. J., Chang, C. F., Lee, J. J., Chen, H. M., Wang, H. J., Liou, Y. L., Yen, C., & Chiang, C. P. (2016). Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer. Oral oncology, 62, 34–43. https://doi.org/10.1016/j.oraloncology.2016.09.007
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518
|
|
Good prognosis ability of Oral-M® in patients with oral precancerous lesion |
New Taipei City, July 1st, 2021. iStat Biomedical Co., Ltd. (iStat Co.), published Oral-M® 5-year follow-up data in Oral Diseasesa.
This is a follow up hospital-based cohort study conducted in 2012-2017, a continuous investigation of 171 patients with normal mucosa and oral potentially malignant disorders (OPMD) from the recruited subjects of Oral-M® clinical performance study at National Taiwan University Hospital (NTUH)a,b.
Oral-M® (ZNF582 methylation test) by its objective and noninvasive nature, can serve as an effective prognostic tool for disease progression, including progression or malignant transformation of oral lesions in patients with normal oral mucosa and OPMDs.Results demonstrate that patients with higher ZNF582 and PAX1 methylation levels at baseline had a higher incidence of disease progression. In particular, ZNF582 methylation level is the only significant and independent predictor of disease progression after several adjustments of studied factors.
- Juan, Y.-C., Su, Y.-F., Bai, C.-H., Fan, Y.-C., Kuo, T.-T., Ko, H.-H., Peng, H.-H., Chiang, C.-P., Fwu, C.-W., & Cheng, S.-J. (2021). ZNF582 hypermethylation as a prognostic biomarker for malignant transformation of oral lesions. Oral Diseases, 00, 1–10. https://doi.org/10.1111/odi.13946
- Cheng, S. J., Chang, C. F., Lee, J. J., Chen, H. M., Wang, H. J., Liou, Y. L., Yen, C., & Chiang, C. P. (2016). Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer. Oral oncology, 62, 34–43. https://doi.org/10.1016/j.oraloncology.2016.09.007
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518